This combined formulation provides both a GHRH analogue (CJC-1295 without DAC / Modified GRF 1-29) and a selective GHRP (Ipamorelin) in a single lyophilised preparation. Research has demonstrated synergistic effects when GHRH and GHRP class peptides are co-administered, resulting in amplified GH pulse amplitude compared to either compound administered alone.
Preclinical models utilise this combination to examine additive and synergistic somatotropic signalling, anabolic pathway investigations, and the interaction of the two primary GH-regulating axes — the hypothalamic GHRH receptor axis and the ghrelin receptor (GHSR-1a) axis. The combination allows researchers to study dual-pathway GH stimulation in a single experimental protocol.
This formulation is frequently employed in research protocols designed to characterise the pharmacodynamics of combined somatotropic stimulation, GH pulse pattern modelling, and downstream IGF-1 effects in animal and cell-based models. The individual components retain their established selectivity profiles within the combination.
Format: Lyophilised powder | Purity: ≥99% by HPLC (each component) | For Research Use Only
